2024
Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosis
2023
Proteomic Panels for Alcohol-Associated Liver Disease: Accurate, but Different Enough From Existing Clinical Tests?
Mezzacappa C, Bhat M. Proteomic Panels for Alcohol-Associated Liver Disease: Accurate, but Different Enough From Existing Clinical Tests? Gastroenterology 2023, 165: 1576. PMID: 37683704, DOI: 10.1053/j.gastro.2023.09.002.Commentaries, Editorials and LettersDo Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review.
Wang L, Grimshaw A, Mezzacappa C, Rahimi Larki N, Yang Y, Justice A. Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 1490-1497. PMID: 37610426, PMCID: PMC10873036, DOI: 10.1158/1055-9965.epi-23-0468.Peer-Reviewed Original ResearchConceptsRoutine risk factorsPancreatic cancerRisk factorsPolygenic risk scoresClinical dataRisk scoreAddition of PRSClinical risk factorsRoutine clinical dataCancer risk predictionDatabase inceptionCancerClinical applicabilityRelevant exposuresGenetic riskRisk predictionCancer-specific polygenic risk scoresScoping ReviewRiskEuropean ancestryPopulation representativeScoresMost studiesAppropriate controlsFactors
2022
Disparities in Access to Endoscopy for Patients With Upper Gastrointestinal Bleeding Presenting to Emergency Departments
Rodriguez NJ, Zheng N, Mezzacappa C, Canavan M, Laine L, Shung D. Disparities in Access to Endoscopy for Patients With Upper Gastrointestinal Bleeding Presenting to Emergency Departments. Gastroenterology 2022, 164: 1044-1046.e4. PMID: 36228735, PMCID: PMC10083188, DOI: 10.1053/j.gastro.2022.10.001.Peer-Reviewed Original ResearchSystems approach to enhance Lynch syndrome diagnosis through tumour testing
Singh V, Mezzacappa C, Gershkovich P, Di Giovanna J, Ganzak A, Gibson J, Sinard J, Xicola RM, Llor X. Systems approach to enhance Lynch syndrome diagnosis through tumour testing. Journal Of Medical Genetics 2022, 60: 533-539. PMID: 36115663, PMCID: PMC10020126, DOI: 10.1136/jmg-2022-108770.Peer-Reviewed Original ResearchConceptsOriginal cohortColorectal adenocarcinomaLynch syndromeTumor testingGenetic testingPercentage of patientsProportion of patientsLynch syndrome diagnosisCG evaluationCancer genetic testingRace/ethnicityCRC testingCohort studyMMR immunohistochemistryLS diagnosisNew diagnosisMMR lossAcademic centersPatientsSyndrome diagnosisCohortCase identificationMethylation testingReferral differencesReferral mechanismsAn Uncommon Cause of Coffee Ground Emesis in a Young Woman With Remote Roux-en-Y Gastric Bypass
Mezzacappa C, Hughes ML, Hung KW. An Uncommon Cause of Coffee Ground Emesis in a Young Woman With Remote Roux-en-Y Gastric Bypass. Gastroenterology 2022, 163: e16-e17. PMID: 35490784, DOI: 10.1053/j.gastro.2022.04.032.Peer-Reviewed Case Reports and Technical Notes
2021
Colorectal Cancer Risk in Lynch Syndrome: Of Genes and More
Mezzacappa C, Llor X. Colorectal Cancer Risk in Lynch Syndrome: Of Genes and More. Gastroenterology 2021, 162: 1358-1360. PMID: 34863785, DOI: 10.1053/j.gastro.2021.11.032.Peer-Reviewed Original Research
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomesSex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure
Gruen J, Caraballo C, Miller PE, McCullough M, Mezzacappa C, Ravindra N, Mullan CW, Reinhardt SW, Mori M, Velazquez E, Geirsson A, Ahmad T, Desai NR. Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure. JACC Heart Failure 2020, 8: 770-779. PMID: 32653446, DOI: 10.1016/j.jchf.2020.04.015.Peer-Reviewed Original ResearchConceptsAdverse eventsVentricular assist deviceClinical outcomesPotential underuseHigh riskAssist deviceEnd-stage heartWomen 65 yearsRisk of deathContinuous-flow LVADYears of ageAdvanced treatment optionsSex differencesHeart transplantationMultivariable adjustmentHeart failureHeart transplantSimilar incidenceTreatment optionsSimilar riskSurvival analysisLVADPatientsDevice malfunctionWomenNeurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices
McCullough M, Caraballo C, Ravindra NG, Miller PE, Mezzacappa C, Levin A, Gruen J, Rodwin B, Reinhardt S, van Dijk D, Ali A, Ahmad T, Desai NR. Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. JAMA Cardiology 2020, 5: 175-182. PMID: 31738366, PMCID: PMC6865330, DOI: 10.1001/jamacardio.2019.4965.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy Questionnaire scoreNeurohormonal blockadeAngiotensin receptor blockersVentricular assist deviceQuality of lifeMineralocorticoid antagonistsReceptor blockersHeart failureWalk testQuestionnaire scoresΒ-blockersEnzyme inhibitorsAssist deviceGuideline-directed medical therapyAngiotensin-converting enzyme inhibitorMechanically Assisted Circulatory SupportHeart failure regimenLeft ventricular assist deviceAdvanced heart failureRetrospective cohort analysisContinuous-flow LVADBetter survival rateOutcomes of interestInteragency RegistryTriple therapy
2019
Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults An INTERMACS Analysis
Caraballo C, DeFilippis EM, Nakagawa S, Ravindra NG, Miller PE, Mezzacappa C, McCullough M, Gruen J, Levin A, Reinhardt S, Mullan C, Ali A, Maurer MS, Desai NR, Ahmad T, Topkara VK. Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults An INTERMACS Analysis. JACC Heart Failure 2019, 7: 1069-1078. PMID: 31779930, DOI: 10.1016/j.jchf.2019.10.004.Peer-Reviewed Original ResearchConceptsYears of ageVentricular assist device implantationAssist device implantationOlder adultsElderly patientsLVAD implantationDevice implantationMultivariate Cox proportional hazards regression modelCox proportional hazards regression modelKaplan-Meier survival estimatesMechanically Assisted Circulatory SupportProportional hazards regression modelsMechanical circulatory support technologyPost-LVAD outcomesHeart failure populationLog-rank testingSerum albumin levelPredictors of survivalPost-LVAD implantationHazards regression modelsPredictors of outcomeAge-specific outcomesAntithrombotic regimenDurable MCSINTERMACS AnalysisClinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure
Miller PE, Caraballo C, Ravindra NG, Mezzacappa C, McCullough M, Gruen J, Levin A, Reinhardt S, Ali A, Desai NR, Ahmad T. Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure. Circulation Heart Failure 2019, 12: e006369. PMID: 31707800, DOI: 10.1161/circheartfailure.119.006369.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease ProgressionFemaleFrailtyHealth StatusHeart FailureHeart-Assist DevicesHumansIntubation, IntratrachealLungMaleMiddle AgedProsthesis DesignQuality of LifeRecovery of FunctionRegistriesRespiratory InsufficiencyRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVentricular Function, LeftConceptsMechanically Assisted Circulatory Support profile 1 patientsVentricular assist device implantationProfile 1 patientsAssist device implantationRespiratory failureInteragency RegistryLVAD implantationCirculatory supportDevice implantationMechanically Assisted Circulatory Support profile 1Right ventricular assist device implantationLeft ventricular assist device implantationAdvanced heart failure patientsEnd-stage heart failureMechanically Assisted Circulatory SupportAdvanced heart failure populationHeart failure populationHeart failure patientsLandmark clinical trialsMechanical circulatory supportContinuous-flow LVADVentricular assist devicePostimplant complicationsFailure patientsLVAD placement